Peptide TruthCheck a supplier
Tracker · letters dated 2024

FDA warning letters to peptide sellers, 2024

3 letters dated 2024 are on record for storefronts in the registry. Each row gives the date printed on the letter, the recipient as the record gives it, the agency's own page and the storefront's status on the day the file was last checked. Other years: 2020, 2021, 2025, 2026 · all years.

Letter dateRecipient, as the record gives itProducts namedStorefront at last checkLetterPages
Prime PeptidesPrime Vitality, Inc. dba Prime Peptides, Santa Barbara, California2 productsOn watchlist fda.gov ↗letter page · file C
Swiss ChemsSwissChems, 42 Broadway, New York2 productsOn watchlist fda.gov ↗letter page · file C
Xcel PeptidesXcel Research LLC, Sheridan, Wyoming7 productsOn watchlist fda.gov ↗letter page · file F

What the record says each letter concerned

From the letter pages

Reader questions

Answered from the file
Which peptide sellers on file received an FDA warning letter in 2024?

Prime Peptides, letter dated 2024-12-10, addressed to Prime Vitality, Inc. dba Prime Peptides, Santa Barbara, California; Swiss Chems, letter dated 2024-12-10, addressed to SwissChems, 42 Broadway, New York; Xcel Peptides, letter dated 2024-12-10, addressed to Xcel Research LLC, Sheridan, Wyoming. The list covers storefronts the desk keeps a file on, not every recipient in the agency's database.

Are the 2024 recipients still trading?

Prime Peptides: on watchlist at the check on 2026-10-19; Swiss Chems: on watchlist at the check on 2026-10-19; Xcel Peptides: on watchlist at the check on 2026-10-19.

Products are described only as GLP-class products or products named in the letter; the agency's own wording is on fda.gov. The tracker lists every year; the watchlist carries closures alongside the letters. Every storefront listed sells material labeled for laboratory research use only.